Biomaterial Co. MiMedx Accused Of Defrauding Investors

Law360, New York (September 23, 2013, 6:55 PM EDT) -- A MiMedx Group Inc. shareholder launched a class action Thursday accusing the biomaterial company of defrauding investors and causing stocks to plummet by making misleading statements about whether a range of tissue products complied with U.S. Food and Drug Administration regulations.

Patricia Gladowski alleges in a suit filed in Georgia federal court that MiMedx, CEO and Chairman Parker Petit, Chief Financial Officer Michael Senken, and President and Chief Operating Officer William Taylor either purposefully omitted or recklessly disregarded the fact that the injectable tissue anti-inflammatory and...
To view the full article, register now.